<div id="readability-page-1"><h3>President's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Sanofi ( (SNY) ) just unveiled an update. On February 9, 2026, Sanofi announced that its oral BTK inhibitor rilzabrutinib, marketed as Wayrilz for immune thrombocytopenia, received U.S. FDA breakthrough therapy designation and orphan drug status in Japan for treating warm autoimmune hemolytic anemia, a rare and potentially life-threatening autoimmune blood disorder. The dual designations, supported by data from the ongoing LUMINA 2 phase 2b and LUMINA 3 phase 3 trials, highlight the absence of targeted therapies for this condition and underscore rilzabrutinib’s broad rare-disease potential, reinforcing Sanofi’s strategic positioning in high‑value rare hematology and immune-mediated indications. The most recent analyst rating on (SNY) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page. Spark’s Take on SNY Stock According to Spark, TipRanks’ AI Analyst, SNY is a Outperform. The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating. To see Spark’s full report on SNY stock, click here. More about Sanofi Sanofi is an R&amp;D-driven, AI-powered biopharmaceutical company focused on discovering and developing medicines and vaccines that leverage its deep expertise in immunology. Listed on Euronext and Nasdaq, the group targets serious immune-mediated and rare diseases, aiming to deliver both improved patient outcomes and sustainable growth through an innovative global pipeline. Average Trading Volume: 3,418,272 Technical Sentiment Signal: Sell Current Market Cap: $111.3B For a thorough assessment of SNY stock, go to TipRanks’ Stock Analysis page.</div>

IBBQ

Sanofi has received U.S. FDA breakthrough therapy designation and orphan drug status in Japan for its oral BTK inhibitor, rilzabrutinib, aimed at treating warm autoimmune hemolytic anemia. This rare blood disorder currently lacks targeted therapies. The designations are based on data from ongoing clinical trials, emphasizing Sanofi's strategic focus on rare hematology. Analysts rate Sanofi's stock (SNY) as a Hold with a $51 price target, while AI analysis suggests an Outperform rating due to strong financial resilience and a positive earnings outlook.

Tip Ranks

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

VG Health

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Sanofi

Ark Genomic Revolution ETF

Sanofi Wins U.S. Breakthrough and Japan Orphan Status for Rilzabrutinib in Rare Anemia